Multiple Sclerosis Drugs Market
Multiple Sclerosis Drugs Market - Global Industry Assessment & Forecast
#
Pages:
147
2022
Oct - 2022
VMR-1859
Segments Covered
By
Drug Class Immunosuppressants, Immunomodulators, Interferons, Other Drug Classes
-
By
Route of Administration Oral, Injectable
-
By
Distribution Channel Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
-
By
Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
 Base Year:
|
2022 |
| Forecast
Years:
|
2023 - 2030 |
 Historical
Years:
|
2017 - 2021 |
 Revenue
2022: |
USD 25.90 Billion |
 Revenue 2030:
|
USD 34.36 Billion |
 Revenue CAGR
(2023 - 2030): |
3.60% |
Fastest Growing Region (2023 -
2030)
|
Asia Pacific |
Largest Region (2022):
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
| Sr. No. | Offering | Report Coverage |
| 1. | Market Size | In terms of Revenue (USD Million) |
| 2. | Historic Data | 2017 to 2021 |
| 3. | Forecast Data | 2023 to 2030 |
| 4. | Market Drivers, Restraints, Opportunities, & Regional Market Trends | Yes |
| 5. | Market Attractiveness Analysis | Yes |
| 6. | Segment Analysis | Maximum Segments |
| 7. | Regional Coverage | 5 Regions |
| 8. | Country Coverage | Top 22 Countries |
| 9. | Competitive Landscape and Company Market Share Analysis | Yes. Exhaustive information will be provided in two separate chapters of Competitive Landscape and Company Profiles. |
| 10. | Porter’s Five Forces Analysis | Yes. |
| 11. | Value Chain Analysis | Yes |
| 12. | PEST Analysis | Yes |
| 13. | Regulatory Landscape | Yes |
| 14. | Technology Landscape | Yes |
| 15. | COVID-19 Impact Analysis | Yes. Exhaustive information for Key Strategies Undertaken by Companies, Impact Assessment of the COVID-19 Pandemic by Region, along with Short-term and Long-term dynamics. |
| 16. | Top startups to watch out for | Yes |
| 17. | Top 3 Trends to Watch | Yes |
| 18. | Top 3 Strategies Followed by Major Players | Yes |
| 19. | Top 3 Predictions by Vantage Market Research | Yes |
| 20. | Discussion Guide | Yes |
| 21. | Key Primary Respondents - VERBATIM | Yes |
| 22. | Transcripts from the Primary Respondents | Additional Cost USD 1,000 |
| 23. | Others/Miscellaneous | |
Vantage Market
Research | 10-Oct-2022
FAQ
Frequently Asked Question
What is the global demand for Multiple Sclerosis Drugs in terms of revenue?
-
The global Multiple Sclerosis Drugs valued at USD 25.90 Billion in 2022 and is expected to reach USD 34.36 Billion in 2030 growing at a CAGR of 3.60%.
Which are the prominent players in the market?
-
The prominent players in the market are Celgene Corporation, Acorda Therapeutics Inc., Biogen Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG., Sanofi, F. Hoffmann-La Roche Ltd..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 3.60% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Multiple Sclerosis Drugs include
- Significant R&D Investment by Market Players to Boost the Market
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Multiple Sclerosis Drugs in 2022.
